Carving a new trail in immunology

First Tracks Biotherapeutics is a clinical‑stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases.

Where bold science becomes action

image of Theresa in the lab

Theresa working in the First Tracks lab

First Tracks Bio is built on a simple but powerful belief: scientific exploration and innovation matter most when they create impact.

Our name reflects the pioneering spirit that drives us. We embrace the courage to go first, the confidence to carve a new trail and the excitement of transforming scientific insight into meaningful impact for all our stakeholders.

Guided by this spirit, we pursue a focused strategy to efficiently advance a high value immunology portfolio that delivers meaningful impact where it’s needed most.

Because patients deserve a future that looks nothing like their past. A future where autoimmune diseases no longer define a life, a family or a dream.

News Releases

First Tracks Events
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences.
First Tracks News
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the third quarter ended Sept. 30, 2026, and provided a business update.
First Tracks News
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 6,106,870 shares of its common stock to a limited group of institutional investors in a private placement at a price of $32.75 per share.